Teva to Present at the Jefferies London Healthcare Conference
November 08 2024 - 4:30PM
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced that Richard Francis, Teva's President and CEO, will
present at the Jefferies London Healthcare Conference on Tuesday,
November 19, 2024. The presentation will begin at 8:30 A.M.
Greenwich Mean Time (3.30 A.M. Eastern Time).
To access a live webcast of the presentation, visit Teva’s
Investor Relations website at
https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24
hours after the end of the live discussion.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
global pharmaceutical leader, harnessing our generics expertise and
stepping up innovation to continue the momentum behind the
discovery, delivery, and expanded development of modern medicine.
For over 120 years, Teva's commitment to bettering health has never
wavered. Today, the company’s global network of capabilities
enables its ~37,000 employees across 58 markets to push the
boundaries of scientific innovation and deliver quality medicines
to help improve health outcomes of millions of patients every day.
To learn more about how Teva is all in for better health, visit
www.tevapharm.com.
Cautionary Note Regarding
Forward-Looking Statements
This document and the presentation at the conference may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, which are based on
management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that
could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our
ability to successfully compete in the marketplace including our
ability to successfully execute our Pivot to Growth strategy,
including to expand our innovative and biosimilar medicines
pipeline and profitably commercialize the innovative medicines and
biosimilar portfolio, whether organically or through business
development, and to sustain and focus our portfolio of generics
medicines; our substantial indebtedness; our business and
operations in general including the impact of global economic
conditions and other macroeconomic developments and the
governmental and societal responses thereto; compliance, regulatory
and litigation matters; other financial and economic risks; and
other factors discussed in our Quarterly Report on Form 10-Q for
the third quarter of 2024 and in our Annual Report on Form 10-K for
the year ended December 31, 2023, including in the sections
captioned "Risk Factors.” Forward-looking statements speak only as
of the date on which they are made, and we assume no obligation to
update or revise any forward-looking statements or other
information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
IR
Contacts |
|
Ran Meir |
+1 (215)
591-8912 |
|
|
Yael Ashman |
+972 (3) 914
8262 |
|
|
Sanjeev
Sharma |
+1 (973) 658
2700 |
PR
Contacts |
|
Kelley
DoughertyEden Klein |
+1 (973)
832-2810+972 (3) 906 2645 |
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Dec 2023 to Dec 2024